Enterprise Value

649.3M

Cash

192.5M

Avg Qtr Burn

-35.92M

Short % of Float

28.46%

Insider Ownership

21.61%

Institutional Own.

85.31%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INBRX-101 (AAT-Fc fusion protein) Details
Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency

Phase 2

Data readout

INBRX-109 (DR5 agonist) Details
Solid tumor/s, Cancer, Chondrosarcoma

Phase 2

Data readout

INBRX-109 (DR5 agonist) Details
Relapsed/refractory Ewing sarcoma

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Data readout